The current stage of cathepsin B inhibitors as potential anticancer agents

Future Med Chem. 2014 Jul;6(11):1355-71. doi: 10.4155/fmc.14.73.

Abstract

Cathepsin B is a lysosomal cysteine peptidase, with an important role in the development and progression of cancer. It is involved in the degradation of extracellular matrix proteins, a process promoting invasion and metastasis of tumor cells and tumor angiogenesis. Cathepsin B is unique among cathepsins in possessing both carboxypeptidase and endopeptidase activities. While the former is associated with its physiological role, the latter is involved in pathological degradation of the extracellular matrix. Its activities are regulated by different means, the most important being its endogenous inhibitors, the cystatins. In cancer this peptidase/inhibitor balance is altered, leading to harmful cathepsin B activity. The latter can be prevented by exogenous inhibitors. They differ in modes of inhibition, size, structure, binding affinity, selectivity, toxicity and bioavailability. In this article, we review the properties and function of endogenous and exogenous cathepsin B inhibitors and indicate their application as possible anticancer agents.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Cathepsin B / antagonists & inhibitors*
  • Cathepsin B / metabolism
  • Cystatins / physiology
  • Cysteine Proteinase Inhibitors / therapeutic use*
  • Humans
  • Neoplasms / drug therapy
  • Neoplasms / enzymology

Substances

  • Antineoplastic Agents
  • Cystatins
  • Cysteine Proteinase Inhibitors
  • Cathepsin B